Proton magnetic resonance spectroscopy of the human brain in schizophrenia

Reviews in the Neurosciences

Volumn 11, Issue 2-3, 2000, Pages 147-158

  Deicken, Raymond F ^a,b   Johnson, Camilla ^a   Pegues, Mary ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain; Choline; Creatine; Magnetic resonance spectroscopy; N acetylaspartate; Neurochemistry; Schizophrenia

Indexed keywords

CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID;

BASAL GANGLION; CELL LOSS; CINGULATE GYRUS; DISEASE MARKER; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; IMAGING; IN VIVO STUDY; NERVE CELL; NERVE FIBER; NERVE FUNCTION; NEUROCHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCHIZOPHRENIA; TEMPORAL CORTEX; THALAMUS; WHITE MATTER;

EID: 0034054805     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.2000.11.2-3.147     Document Type: Review

References (53)

1. Barker PB, Breiter SH, Soher BJ, Chatham JC, Forder JR, Samphilipo MA, Magee CA, Anderson JH. Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med 1994; 32: 157-163.
2. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran G, Rylett J, Neufeld RWJ. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiat 1997; 54: 959-963.
3. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CTW, Frank JA, Tedeschi G, Weinberger DR. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multi-slice proton magnetic resonance spectroscopic imaging. Am J Psychiat 1996; 153: 1554-1563.
4. Bertolino A, Saunders R, Mattay V, Bachevalier J, Frank J, Weinberger D. Altered development of prefrontal neurons in rhesus monkeys with neonatal mesial temporo-limbic lesions: a proton magnetic resonance spectroscopic imaging study. Cereb Cortex 1997; 7: 740-748.
5. 1H-magnetic spectroscopic imaging correlates with rCBF activation during working memory in patients with schizophrenia. Neuroimage 1997; 5: S281.
6. Bertolino A, Callicott JH, Elman I, Duyn JH, Tedeschi G, Frank JA, Pickar D, Weinberger DR. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiat 1998; 43: 641-648.
7. Bertolino A, Kumra S, Callicott J, Mattay VS, Lestz RM, Jacobsen L, Barnett IS, Duyn JH, Frank JA, Rapoport JL, Weinberger DR. A common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am J Psychiat 1998; 155: 1376-1383.
8. Bertolino A, Knable MB, Saunders RC, Callicott JH, Kolachana B, Mattay VS, Bachevalier J, Frank JA, Egan M, Weinberger DR. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol Psychiat 1999; 45: 660-667.
9. Brooks WM, Hodde-Vargas, J, Vargas LA. Yeo RA, Ford CC, Hendren RL. Frontal lobe of children with schizophrenia spectrum disorders: a proton magnetic resonance spectroscopic study. Biol Psychiat 1998; 43: 263-269.
10. 1H magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol Psychiat 1994; 36: 792-800.
11. Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJP, Frank J, Weinberger DR. Hippocampal N-acetyl-aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiat 1998; 44: 941-950.
12. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad Radiol 1994; 1: 211-216.
13. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 1996; 31: 345-352.
14. Crowe RR. Candidate genes in psychiatry: an epidemiological perspective. Am J Med Genet 1993; 48: 74-77.
15. Deicken RF, Ling Z, Corwin F, Vinogradov S, Weiner MW. Decreased left frontal lobe N-acetylaspartate in schizophrenia. Am J Psychiat 1997; 154: 688-690.
16. Deicken RF, Zhou L, Schuff N, Weiner MW. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophr Res 1997; 27: 65-71.
17. Deicken RF, Zhou L, Schuff N, Fein G, Weiner MW. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiat 1998; 43: 483-488.
18. Deicken RF, Pegues M, Amend D. Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia. Schizophr Res 1999; 37: 217-223.
19. Deicken RF, Johnson C, Eliaz Y, Schuff N. Decreased thalamic N-acetylaspartate in male patients with schizophrenia. Am J Psychiat; in press.
20. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995; 34: 721-727.
21. Deutch AY. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 1992; 36: 61-89.
22. Dwork AJ. Postmortem studies of the hippocampal formation in schizophrenia. Schizophrenia Bull 1997; 23: 385-402.
23. 1H NMR spectra of human brain in vivo. NMR Biomed 1991; 4: 201-204.
24. Fujimoto T, Nakano T, Takano T, Takeuchi K, Yamada K, Fukuzako T, Akimoto H. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biol Psychiat 1996; 40: 14-18.
25. Fukuzako H, Takeuchi K, Hokazono Y, Fukuzako T, Yamada K, Hashiguchi T, Obo Y, Ueyama K, Takigawa M, Fujimoto T. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia. Psychiat Res-Neuroimag 1995; 61: 193-200.
26. Heckers S. Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems. Schizophrenia Bull 1997; 23: 403-421.
27. Heimberg C, Komoroski RA, Lawson WB, Cardwell D, Karson CN. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiat Res-Neuroimag 1998; 83: 105-115.
28. 1H magnetic resonance spectroscopic imaging. Ann Neurol 1996; 40: 236-239.
29. Keltner JR, Wald LL, Christensen JD, et al. A technique for detecting GABA in the human brain with PRESS localization and optimized refocusing spectral editing radiofrequency pulses. Magn Reson Med 1996; 36: 458-461.
30. Kidd KK. Can we find genes for schizophrenia? Am J Med Genet 1997; 74: 104-111.
31. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia: a systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiat 1998; 172: 110-120.
32. Lim KO, Adalsteinsson E, Spielman D, Sullivan EF, Rosenbloom MJ, Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiat 1998; 55: 346-352.
33. Maier M, Ron MA, Barker GJ, Tofts PS. Proton magnetic resonance spectroscopy: an in-vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol Med 1995; 25: 1201-1209.
34. Maier M, Ron MA. Hippocampal age-related changes in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 1996; 22: 5-17.
35. Mason GF, Pan JW, Ponder SL, Tweig DB, Pohost GM, Hetherington HP. Detection of brain glutamate and glutamine in spectroscopic images at 4.1 T. Magn Reson Med 1994; 32: 142-145.
36. 1H MRS) of the hippocampal formation in schizophrenia: a pilot study. Br J Psychiat 1994; 165: 481-485.
37. Nelson MD, Saykin AJ, Flashman AL, Riordan HJ. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiat 1998; 55: 433-440.
38. Okumura N, Otsuki S, Nasu H. The influence of insulin hypoglycemic coma, repeated electroshocks, and chlorpromazine or beta-phenylisopropylmethylamine administration on the free amino acids in the brain. J Biochem (Tokyo) 1959; 46: 247-252.
39. Prichard JW, Schulman RG. NMR spectroscopy of brain metabolism in vivo. Ann Rev Neurosci 1986; 9: 61-85.
40. 1H magnetic resonance spectroscopy study. Magn Reson Med 1995; 33: 595-600.
41. Renshaw PF, Yurgelun-Todd DA, Tohen M, Gruber S, Cohen BM. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiat 1995; 152: 444-446.
42. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 1994; 10: 191-247.
43. 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci USA 1993; 90: 5662-5666.
44. Sharma R, Venkatasubramanian PN, Barany M, Davis JM. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res 1992; 8: 43-49.
45. Shioiri T, Hamakawa H, Kato T, Murashita J, Fujii K, Inubushi T, Takahashi S. Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia. Schizophr Res 1996; 22: 19-26.
46. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, Thompson RT. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull 1996; 22: 597-609.
47. Tedeschi G, Bertolino A, Righini A, Campbell G, Raman R, Duyn J, Moonen C, Alger J, DiChiro G. Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology 1995; 45: 1384-1391.
48. Tofts PS, Wray S. A critical assessment of methods of measuring metabolite concentrations by NMR spectroscopy. NMR Biomed 1988; 1: 1-10.
49. Tsai G, Coyle JT. N-Acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995; 46: 531-540.
50. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman J, Coyle JT. Abnormal excitatory neurotransmitter metabolism in schizophrenia brains. Arch Gen Psychiat 1995; 52: 829-836.
51. Williamson P, Pelz D, Merskey H, Morrison S, Karlik S, Drost D, Carr T, Conlon P. Frontal, temporal, and striatal proton relaxation times in schizophrenic patients and normal comparison subjects. Am J Psychiat 1992; 149: 549-551.
52. Yurgelun-Todd DA, English CD, Cohen BM, Renshaw PF. Abnormal proton relaxation times in schizophrenia: an echo-planar study. Proc Soc Magn Reson Med 1995; 2: 1239.
53. Yurgelun-Todd DA, Renshaw PF, Gruber SA, Waternaux C, Cohen B. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr Res 1996; 19: 55-59.